Comparing two diabetes drugs for blood sugar and heart health
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests a new diabetes medicine called Enavogliflozin against an older drug, Pioglitazone, to see which works better for lowering blood sugar and improving heart health. If you have type 2 diabetes, take metformin plus another pill, and your A1C is between 7 and 10.5, this study may be an option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes with an A1C (average blood sugar) between 7.0% and 10.5%.
- You are 20 to 80 years old.
- You have been taking metformin (at least 500 mg daily) with or without a second diabetes pill (like Januvia or Galvus) for at least 3 months.
- Your body mass index (BMI) is 23 or higher.
- Your kidney function (eGFR) is 60 or above.
- You do not have heart failure, recent heart attack/stroke, active cancer, or chronic hepatitis B/C, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three common diabetes medications (metformin, an SGLT2 inhibitor, and a TZD) to see how well they work together and if they are safe. It may help people with type 2 diabetes who need better blood sugar control.
This trial compares two medications, dapagliflozin and empagliflozin, to see which works better and is safer for people with type 2 diabetes and a high body mass index (BMI). If you are an adult with type 2 diabetes and a BMI of 23 or higher, this study might help find a treatment that also supports weight loss.
This trial tests how combining a ketone supplement with certain diabetes medicines affects blood sugar and ketone levels. It may help adults with type 2 diabetes who are not on insulin or certain other drugs.
This trial compares adding a new pill (cofrogliptin) to increasing your current metformin dose, for people whose blood sugar is still too high despite taking an SGLT2 inhibitor and a low dose of metformin. The goal is to see which option works better and is safer.
This study is testing two different diabetes pills—dapagliflozin or pioglitazone—in people with type 2 diabetes. The goal is to see which one works better when added to your current metformin and DPP-4 inhibitor. You may qualify if your blood sugar is not well controlled with your current medications.
This trial tests enavogliflozin (a newer SGLT2 inhibitor) compared to older drugs (dapagliflozin or empagliflozin) to see how well it protects the heart and kidneys in people with type 2 diabetes.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.